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 AARP submits this brief as an amicus curiae pursuant to Fed. R. App. P. 
29(a) and Rule 29(c) of this Court.  Both the Plaintiffs-Appellees and the  
Defendants-Appellants have consented to the filing of this brief. 
     INTEREST OF AMICUS CURIAE 
 AARP is a nonpartisan, nonprofit organization dedicated to addressing the 
needs and interests of people age fifty and older.  AARP seeks through education, 
advocacy and service to enhance the quality of life for all by promoting 
independence, dignity, and purpose.  In its efforts to promote independence, AARP 
works to foster the health and economic security of individuals as they age by 
attempting to ensure the availability of quality and economical health coverage.  
AARP has a long history of advocating for access to affordable health care and for 
controlling costs without compromising quality.   
 Access to affordable health care is particularly important to the older 
population who have higher rates of chronic and serious health conditions.   
Genetic tests are capable of diagnosing a variety of diseases, assessing the risk of 
future disease, and enabling treatment to be tailored to individual genetic 
variations.  In 2008, the AARP Public Policy Institute sponsored a roundtable with 
the National Human Genome Research Institute and the National Institutes of 
Health entitled Genomics and Older Adults:  Policy, Practice and Promise of 21st 
Century Medicine which was held at AARP.  AARP has also published a consumer 
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fact sheet on the Genetic Information Nondiscrimination Act of 2008 (Pub. L. No. 
110-233) (“GINA”).1
ARGUMENT 
  Patents such as those present in this case prohibit diagnosis 
and treatment based on second medical opinions and discourage full medical 
testing.  A patent will also significantly elevate the cost of genetic testing.  
Currently many women decide whether or not to have breasts or ovaries removed 
based on tests that cannot be independently repeated.  In light of the significance of 
the issue presented in this case, AARP respectfully submits this amicus curiae 
brief urging the Court to find that the patents are invalid. 
I. HUMAN GENES & DNA MOLECULES ARE NOT PATENT 
ELIGIBLE UNDER 35 USC §101. 
 
 DNA molecules and human genes are natural phenomena that when 
discovered are not the kind of “discovery” that Section 101 was designed to 
protect.  It has long been clear that the manifestations of the laws and products of 
nature are not patent eligible.  Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 
127, 130 (1948).   See also Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) 
(“The laws of nature, physical phenomena, and abstract ideas have been held not 
                                               
1  N. Lee Rucker, AARP Public Policy Institute, The GINA Law: Consumer 
Protection in a New Era of Genetic Testing (2009), http://assets.aarp.org/ 
rgcenter/health/fs156_gina.pdf.   
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patentable.”); Diamond v. Diehr, 450 U.S. 175, 185 (1981).  “Mere recognition” of 
an already existing phenomenon is not patentable.  Parker v. Flook, 437 U.S. 584, 
593 n. 15 (1978) (“Patentable subject matter must be new (novel); not merely 
heretofore unknown.”).  Further, insignificant physical steps cannot transform 
unpatentable natural phenomena into a patentable invention.  In Wood-Paper 
Patent, 90 U.S. 566 (1874), the Court found that merely removing pulp from straw, 
wood, or other natural sources did not make it a patentable new composition of 
matter: “A process to obtain it [an extract] from a subject from which it has never 
been taken may be the creature of invention, but the thing itself when obtained 
cannot be called a new manufacture.”  Id. at 593-94.  Similarly, isolating a gene 
from the human body does not then make the gene itself, patentable.  Thus, human 
genes and DNA molecules, regardless of whether they are isolated or not, are 
natural phenomena and therefore are not patent eligible under 35 U.S.C. §101. 
II. PUBLIC HEALTH CONSIDERATIONS DEMAND THAT THE   
 PATENTS IN QUESTION BE DENIED. 
 
 In its Opening Brief, Myriad notes the “incalculable societal benefits” 
genetic testing offers and suggests that “future developments will slow or cease” 
without patent protection.  Myriad Op. Br. 3-4, citing A3488; A456; A5700-02; 
A5811-75.  Myriad, however, fails to discuss potential patient harm if the patents 
are upheld, even though this Court has looked at such harm if the patents are 
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upheld.  Cf. Datascope Corp. v. Kontron, Inc., 786 F.2d 398 (Fed. Cir. 1986) 
(Court considered potential patient harm in denying injunctive relief for patent 
infringement).  In this case the public interest demands that the patents in question 
be denied since many individuals will be harmed if the patent is upheld because 
genetic testing will be denied to them either due to cost or unavailability of a 
second opinion.   
A. Gene Patents Impede The Ability Of Patients To Obtain A Second 
Opinion From Other Medical Professionals 
 
Information about human genetic data is accumulating at an ever-increasing 
pace.  Charles N. Rotimi & Lynn B. Jorde, Ancestry and Disease in the Age of 
Genomic Medicine, 363 New Eng. J. Med. 1551 (2010).  “Unquestionably, 
genomics provides novel insights into the causes of and susceptibility to disease 
and adverse reactions to drugs.”  Id. at 1556.  Alzheimer disease, colon and other 
cancers, in addition to breast cancer are a few of the many diseases subject to 
genetic testing.   
Information gained from genetic tests can have a profound impact on 
medical decision making.  Kathy L. Hudson et al., Oversight of US Genetic Testing 
Laboratories, 24 Nature Biotechnology 1083, 1089 (2006).  Test results can lead to 
important, life-changing decisions, such as whether to undergo prophylactic 
mastectomy or take a particular drug or dosage of a drug.  Id. at 1083.  Incorrect 
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test results and laboratory errors can lead to “misdiagnosis, inappropriate and/or 
delayed treatment, anxiety and in rare cases, even death.”  Id. at 1089.  In the 
relative few instances where BRAC testing was done by other laboratories, 
occasional different interpretations of genetic sequences and different results were 
obtained.  See Tom Walsh et al., Spectrum of Mutations in BRCA1, BRCA2, 
CHEK2, and TP53 in Families at High Risk of Breast Cancer, 295 J. Am. Med. 
Ass’n 1379 (2006). 
Beginning in 2002 and over the next three years, a study was conducted of 
300 individuals who had negative test results from Myriad’s BRAC analysis but 
came from families in the United States, each of which included four or more 
members with breast or ovarian cancer.  Id. Myriad’s BRAC analysis at that time 
tested for only five specific mutations in the BRCA1 and BRCA2 genes.  See id. at 
1380.  Using multiple methods of genetic testing, unlike BRAC analysis, the study 
found that 35 of the 300, or in other words 12% of the individuals, carried 
previously undetected BRCA1 or BRCA2 genetic mutations.  See id. at 1379.  
Walsh went on to conclude: 
[G]enetic testing, as currently carried out in the United States, does not 
provide all available information to women at risk . . . [since] 12% of those 
from high risk families with breast/ovarian cancer and with negative . . . 
commercial genetic test results for BRCA1 and BRCA2 nonetheless carry 
cancer-predisposing genomic deletions or duplications in one of these genes.   
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Id. at 1386.  Because an individual with a high risk of breast or ovarian 
cancer may consider having an invasive and expensive surgical procedure such as 
a mastectomy, it is extremely important that those who undergo BRCA genetic 
testing receive accurate and thorough testing and results.  See id.  Walsh also notes 
that “participation in research studies is not an adequate substitute for providing 
the most effective and thorough clinical genetic testing.”  Id.  While Myriad claims 
these discrepancies are rare and their tests are now improved, clearly individuals 
seeking any type of genetic testing should have the option of securing a second 
opinion which can have life altering results. 
Other geneticists have reached different conclusions from Myriad indicating 
the importance of allowing patients access to second opinions regarding their 
genetic sequences.  In 2001, Dr. Sophia Gad, Dr. Dominique Stoppa-Lyonnet, and 
a host of other French geneticists identified a large mutation in one woman’s 
BRCA1 gene which was undiscovered by Myriad.  See Sophia Gad et al., 
Identification of a Large Rearrangement of the BRCA1 Gene Using Colour Bar 
Code on Combed DNA in an American Breast/Ovarian Cancer Family Previously 
Studied by Direct Sequencing, 38 J. Med. Genetics 388 (2001).  See also Declan 
Butler & Sally Goodman, French Researchers Take a Stand Against Cancer Gene 
Patent, 413 Nature 95 (2001).  The woman who participated in this study was 
diagnosed with breast cancer at age 30 and ovarian cancer at age 49.  See Gad et 
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al., supra.  She also had a sister with ovarian cancer (diagnosed age 35), a sister 
with breast cancer (diagnosed age 35), and a grandmother with breast cancer 
(diagnosed age 41).  See id.  She sought testing in an effort to help her daughter 
identify her specific genetic status with respect to her predisposition to breast and 
ovarian cancer.  See id.   
The ability to send a sample to a second laboratory is important not only for 
the patient but also for a laboratory that may receive confusing or unexpected 
results.  See, e.g., Karen P. Mann, Gene Patents, Perspectives from the Clinical 
Laboratory, 14 J. Molecular Diagnosis & Therapy 137, 139 (2010).  Confirmatory 
testing by another laboratory is the “laboratory equivalent to the time-honored 
practice of obtaining a second opinion from a clinician.”  U.S. Dept. of Health & 
Hum. Serv., Gene Patents and Licensing Practices and Their Impact on Patient 
Access to Genetic Tests: Report of the Secretary's Advisory Committee on 
Genetics, Health, and Society 44 (2010), available at http://oba.od.nih.gov/oba/ 
SACGHS/reports/SACGHS_patents_report_2010.pdf.  (“Access to confirmatory 
testing is completely impeded when a patent-enabled sole provider exists.  That is, 
patients who desire a confirmatory test from a second laboratory are unable to 
obtain this second-opinion test in those cases where the patents right holder has 
cleared the market of other laboratories offering the test.”).   
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B. It Is Critical That Patients Have The Option Of A Second 
Opinion Given The Limited Governmental Oversight Over 
Genetic Tests. 
 
The U.S. Dept. of Health and Human Services’ Advisory Committee on 
Genetics, Health & Society, notes that “significant concerns about the quality of a 
genetic test arise when it is provided by a patent-protected sole provider.”  Id. at 4.  
The report identified that the “most robust” method for assuring quality in 
laboratory testing is through the “comparison of results obtained on samples shared 
between different labs.”  Id.  Moreover, the Advisory Committee notes that: 
The presence of multiple laboratories offering competing genetic testing for 
the same condition can also lead to improvements in the overall quality of 
testing through innovation in developing novel and more thorough 
techniques of testing.   Neither sample sharing nor competition is possible 
when an exclusive-rights holder prevents others from providing testing.   
Id. 
 
Most commercially available genetic tests do not encounter the level of 
government oversight that accompanies the introduction of pharmaceuticals in the 
marketplace.  Eileen M. Kane, Patent-Mediated Standards in Genetic Testing, 
2008 Utah L. Rev 835, 842 (2008).  As a result, a restrictive gene patenting 
scenario can converge with the lax regulatory climate so that a genetic test may not 
receive optimal peer assessment.  Id.  Most tests are developed in-house by clinical 
laboratories and are not subject to government review before they are made 
clinically available.  Hudson, supra, at 1083.   
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When tests are offered by multiple laboratories, quality typically is assessed by the 
use of international standards as well as by comparison with peers.  Mann, supra at 
139.  Obviously, this cannot be done where only a single laboratory conducts 
testing.  With the best proficiency testing, a laboratory will be sent well 
characterized samples from an external organization or agency to test.  
Laboratories get information as to what methodology and technology other 
laboratories are using and how the performance of those laboratories compares.  
“In the absence of this type of proficiency testing, the ability of the lab to know 
how well they are doing is impaired.”  Id.  Without multiple provider laboratories 
and this type of proficiency testing, there is simply no way of knowing how 
proficient a given laboratory is.  Id. 
III.     GENE PATENTS LIMIT THE ACCESSIBILITY OF 
COMPETITIVELY PRICED GENETIC TESTING SO THAT 
 MANY PATIENTS CANNOT AFFORD TESTING. 
 
While advances in genetics and genomics are driving the development of 
new genetic tests and services, “problems with coverage and reimbursement are 
limiting their accessibility and integration into the health care system.”  U.S. Dep’t 
of Health & Hum. Serv., Coverage and Reimbursement of Genetic Tests and 
Services:  Report of the Secretary's Advisory Committee on Genetics, Health, and 
Society, 9 (2006), available at http://www4.od.nih.gov/oba/sacghs/reports/CR_ 
report.pdf (hereafter Coverage and Reimbursement).    
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Human gene patents can affect patient access through the assignment of 
exclusive licenses to perform genetic tests.  “Exclusive licensing increases cost, as 
there is a lack of competition.”  Mann, supra, at 139.  In addition, there is an 
increased processing cost for sending out samples and sole provider laboratories 
may not accept a patient’s insurance.   Id.   
In general, gene patents limit the accessibility of competitively priced 
genetic testing services because of “monopolistic licensing that limits a given 
genetic test to a single laboratory, royalty-based licensing agreements with 
exorbitant up-front fees and per-test fees, and licensing agreements that seek 
proportions of reimbursement from testing services.”  American College of 
Medical Genetics, Position Statement on Gene Patents and Accessibility of Gene 
Testing (1999) http://www.acmg.net/StaticContent/StaticPages/Gene_Patents.pdf.  
“By their nature, patents create an environment of exclusion, and consequently, 
cripple competition” (Schering-Plough Corp. v. F.T.C., 402 F.3d 1056, 1065-66 
(11th Cir. 2005), cert. den’d, 548 U.S. 919 (2006)) resulting in elevated prices for 
the consumer.  There are significant numbers of Americans (50.7 million) who are 
still uninsured. 2
                                               
2  U.S. Census Bureau, Income, Poverty, and Health Insurance Coverage in the 
United States: 2009, 22 (2010), available at http://www.census.gov/prod/2010 
pubs/p60-238.pdf. 
  The cost of health care frequently determines whether or not 
people receive health care.  “The failure to obtain health care in a timely fashion is 
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associated with negative outcomes, including more costly care, delays in diagnosis 
or treatment and poorer health outcomes, and premature death.”  Stefanie 
Mollborn, Irena Stepanikova, & Karen S. Cook, Delayed Care and Unmet Needs 
among Health Care System Users: When Does Fiduciary Trust in a Physician 
Matter?, 40 Health Services Research 1898, 1899 (2005). 
A. The Cost of Myriad’s BRCA Genetic Testing and Limited 
Medicare Coverage 
 
Myriad’s BRCA genetic testing is expensive, with the most comprehensive 
tests costing in excess of $4,000, for full sequencing plus rearrangement testing.  
See Myriad Genetic Laboratories, Advanced Beneficiary Notice of Non-Coverage, 
http://www.myriad.com/lib/abn/Myriad-ABN.pdf (last visited Nov.16, 2010); 
Myriad Raises Price of BRCA Testing, Again, Yale Cancer Genetic Counseling, 
April 19, 2010, http://yalecancergeneticcounseling.blogspot.com/2010/04/myriad-
raises-price-of-brca-testing.html.  Medicare is the largest provider of health 
insurance in the United States3 and its current coverage policy of genetic testing is  
limited.4
                                               
3  See Medicare.gov, Medicare Benefits, http://www.medicare.gov/navigation/ 
medicare-basics/medicare-benefits/medicare-benefits-overview.aspx (last visited 
Nov. 30, 2010).  Medicare is a Health Insurance Program for people age 65 or 
older, some disabled people under age 65, and people of all ages with End-Stage 
Renal Disease. 
  Most Medicare beneficiaries live on modest incomes and simply cannot 
  
4  Id. at 30. 
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afford to pay the elevated costs of patented genetic tests.  In 2006, the annual 
median income among Medicare beneficiaries was $22,800.  Nearly half of all 
beneficiaries (44 percent) have annual family incomes of $20,000 or less.  Kaiser 
Family Found., Medicare Chartbook 15 (4th ed. 2010), available at 
http://facts.kff.org/chartbook.aspx?cb=58.  Medicare coverage decisions are made 
at both the national and local levels.  U.S. Dep’t of Health & Human Servs., 
Coverage and Reimbursement, supra, at 28. 
The U.S. Department of Human and Health Services notes that: 
Most local Medicare administrative contractors do not cover predictive 
BRCA1/2 testing because they consider it to be a screening test, which 
[Centers for Medicare and Medicaid Services] has interpreted not to be a 
statutory benefit.  However, a few local Medicare administrative 
contractors have decided to allow coverage of BRCA testing performed 
in the absence of signs, symptoms, or a personal history of the disease.  
The result is that Medicare coverage of the BRCA1/2 genetic test varies 
depending on where in the United States the beneficiary lives. 
 
Id. at 28.  “Different local coverage policies can lead to inconsistencies in coverage 
from one region to another.”  Id.  In some states Medicare will cover the cost of the 
test if the beneficiary has “a personal history of cancer, injury, or signs/symptoms 
thereof (i.e. clinically affected)” in addition to one or more of the following:  (1) 
the beneficiary was diagnosed at or before age 45, (2) the beneficiary was 
diagnosed at or before age 50 or two breast primaries, with one or more close 
blood relative(s) with epithelial ovarian/fallopian tube/primary peritoneal cancer, 
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(3) two breast primaries when first breast cancer diagnosis occurred prior to age 
50, (4) diagnosed at any age, with two or more close blood relatives with breast 
and/or epithelial ovarian/fallopian tube/primary peritoneal cancer at any age, (5) 
Close male blood relative with breast cancer, (5) personal history of epithelial 
ovarian/fallopian tube/primary peritoneal cancer, (6) if of ethnicity with higher 
mutation frequency (e.g. Ashkenazi Jewish, Icelandic), no additional family history 
required, or (7) a close relative with a known BRCA1 or BRCA2 gene mutation.5
However, “[p]redictive or pre-symptomatic genetic tests and services in the 
absence of a past or present illness in the beneficiary, are not covered under 
national Medicare rules;” for instance, “Medicare does not cover genetic tests 
based on family history alone.”  See Ctr. Medicare & Medicaid Serv., LCD for 
Genetic Testing (L24308) (updated Nov. 21, 2010); Ctr. Medicaid & Medicare 
Serv., Medicare Claims Processing Manuel, Ch.16, Rule 120.1 (2009)(“Tests that 
are performed in the absence of signs, symptoms, complaints, personal history of 
disease, or injury are not covered except when there is a statutory provision that 
explicitly covers tests for screening as described.”). 
   
                                               
5  See Ctr. Medicare & Medicaid Serv., LCD for Genetic Testing (L23664) 
(updated Nov. 21, 2010); Ctr. Medicare & Medicaid Serv., LCD for Genetic 
Testing (L24308) (updated Nov. 21, 2010).  
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Medicare generally precludes coverage of genetic testing to those people 
who have not yet been diagnosed with cancer (“testing of unaffected family 
members or other individuals is considered by Medicare to be screening and is not 
payable under the Medicare program.”).  See Ctr. Medicare & Medicaid Serv., 
LCD for Genetic Testing (L24308) (updated Nov. 21, 2010).  Requiring that 
Medicare recipients wait until they actually have contracted cancer reduces one of 
the most significant benefits of the testing to those BRAC carriers who have not 
yet contracted cancer but may do so in the future.  The most obvious benefit of 
genetic testing for the BRCA genes is that women with positive test results become 
aware of their high cancer risk, and, as a result, may follow a suitable preventative 
strategy to reduce their risk of ever contracting the disease.  See Marzia Palma et 
al., BRCA1 and BRCA2:  The Genetic Testing and The Current Management 
Options For Mutation Carriers, 57 Critical Rev. in Oncology/Hematology 1, 16 
(2006).  For carriers of BRCA1 and BRCA2 mutations, the risk of developing 
breast cancer has been reported to be as high as 87%.  See Michael J. Hall et al., 
BRCA1 and BRCA2 Mutations in Women of Different Ethnicities Undergoing 
Testing for Hereditary Breast-Ovarian Cancer, 115 Cancer 2222, 2223 (2009).  
Unfortunately, most Medicare recipients, living on modest incomes, cannot afford 
the elevated cost of patented genetic testing.  
 
15 
 
B.  Limited Medicaid Coverage of Genetic Tests and Services 
Medicaid covers 45% of all poor Americans.  Kaiser Family Found., 
MEDICAID - A Primer, Key Information on Our Nation’s Health Coverage 
Program for Low-Income People 7 (2010), available at http://www.kff.org/ 
medicaid/upload/7334-04.pdf.  “Overall, Medicaid beneficiaries are much poorer 
and in markedly worse health than low-income people with private insurance.”  Id.  
Medicaid is administered by the states but funded jointly by the state and federal 
governments.6
 While Myriad does have a special financial assistance program, patients who 
are recipients of Medicaid or Medicare are not eligible to apply.  Myriad, Payment 
  The Federal government mandates that certain benefits be provided 
to Medicaid recipients, and the States have discretion to cover additional benefits.  
With the exception of newborn screening, genetic tests and services are optional 
Medicaid benefits.  U.S. Dep’t of Health & Human Servs., Coverage and 
Reimbursement, supra, at 5.  A number of State Medicaid programs cover BRAC 
analysis for qualifying individuals, but state requirements vary.  Facing Our Risk 
of Cancer Empowered (FORCE), Medicaid Coverage of Genetic Testing, 
http://www.facingourrisk.org/info_research/finding-health-care/financial-
help/index.php (last visited Dec 6, 2010). 
                                               
6  Kaiser Family Found., MEDICAID - A Primer, supra, at 5. 
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Options and Health Insurance Reimbursement, http://www.myriadtests.com/index. 
php?page_id=51&usetemplate=pathome&usetype=1 (last visited Dec 6, 2010).    
 Given the limited coverage of genetic testing for Medicare and Medicaid 
patients many patients must pay for genetic testing out of their own pockets.  
Rejecting the patents in this case and allowing more laboratories to do the tests will 
result in lower prices for the tests and greater patient access. 
CONCLUSION 
 For all of the above-referenced reasons, the judgment of the district court 
should be affirmed. 
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